Nicholas Choong

Company: Seagen

Job title: Vice President of Clinical Development

Seminars:

Disitamab Vedotin: A Novel HER2 ADC 9:30 am

– Disitamab vedotin is a HER2 ADC with an antibody designed to maximize drug delivery with higher affinity and internalization rate as compared to trastuzumab in preclinical models – Exploring DV’s encouraging monotherapy clinical data across a range of HER2 expressing solid tumors – Understanding how DV has demonstrated combination activity preclinically and clinically with…Read more

day: Day One